Novo Nordisk set to release Ozempic
PLAINSBORO, N.J. — Novo Nordisk this week gained Food and Drug Administration approval for Ozempic (semaglutide injection), a medication for type 2 diabetes. Also this week, Novo Nordisk and pharmacy benefit manager Prime Therapeutics said they signed a value-based contract for Victoza (liraglutide injection), another type 2 diabetes medication. A glucagon-like peptide (GLP-1) receptor agonist,
